Loading…
Loading…
2B4.F does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 2B4.F and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 2B4.F and 80,000+ other tickers.
See exactly how 2B4.F's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 2B4.F and 80,000+ other tickers.
Bonesupport Holding AB (publ) is a specialized orthobiologics firm dedicated to the creation and global commercialization of injectable bioceramic bone graft substitutes, designed to effectively treat bone voids. Its innovative solutions are distributed across Europe, North America, and other international territories. The company's key offerings include CERAMENT Bone Void Filler, a synthetic, injectable material that is both moldable and drillable, formulated with hydroxyapatite, calcium sulfate, and the radiopaque agent iohexol. Furthermore, Bonesupport provides CERAMENT G, a ceramic bone…
No recent news available.